Associate Director, Case Management Intake & Submissions in Maidenhead

The Opportunity: CSL's R&D organization is accelerating innovation to deliver greater impact for patients. With a project-led structure and a focus on collaboration, we’re building a future-ready team that thrives in dynamic biotech ecosystems. Joining CSL now means being part of an agile team committed to developing therapies that make a meaningful difference worldwide. We are looking for an Associate Director, Case Management Intake & Submissions to join our R&D team.

Under Case Intake, you will be responsible for the oversight of the Global Adverse Events Inbox, and all other Intake sources within CSL. You will also be responsible for ensuring accurate and timely entry of reports into the global safety database by the vendor. Under Case Submissions, you will be responsible for providing accurate implementation of global electronic ICSR reporting with Regulators, Partners or internal customers. Additionally, you will proactively monitor successful reporting and resolve submission failures to minimize impact to regulatory compliance.

The Case Submission aspect of the function has a high business impact as reporting compliance is potentially affected and will require ability to analyze varied regulatory sources and engage readily with diverse stakeholders and Regulatory Authorities. You will lead a team responsible for continuous analysis of global documents and regulatory intelligence from interface functions to decide on relevant updates to regulatory and business reporting requirements.

The Role: Reporting to the Sr. Director, Global Case Management, you will:

• Oversee intake and triage of all incoming safety data (spontaneous, literature, partner reports).
• Monitor outbound submissions to regulators, affiliates, and partners, including E2B tracking and acknowledgments.
• Coordinate follow-up activities, ensuring timely and appropriate vendor queries and responses.
• Provide oversight to ensure global reporting compliance with country specific Regulatory and Business requirements related to expedited adverse event reporting.
• Regularly analyze complex regulatory intelligence underpinning reporting requirements.
• Completion of impact review within defined timelines and closely collaborate with WAVES team, IT and interface functions to ensure accurate and timely changes to expedited reporting requirements are adequately implemented to meet regulatory obligations.
• Continuous monitoring and supporting improvements on electronic submission of Individual Case Safety Reports (ICSRs):

• Daily Monitoring of reporting and reportability of processed cases in Argus Safety database. Analyze underlying cause of missed reports and take timely action to minimize compliance impact.
• Liaise with Case Processing Lead and/or Case Management vendor to implement case corrections and training if required.
• Close collaboration with WAVES team, IT, International Pharmacovigilance (IPV) & Capability Building and other interface functions to identify opportunities of process improvement.

• Review of study reporting plans and reporting responsibility matrix in close cooperation with GSPV Clinical Trial Liaison, Risk Management, Clinical Operations and Clinical Research Organizations.
• Review the monthly notifications (Veeva) for study status including country approval status and update reporting requirements as required.

• Review relevant business documentation (ODCS notifications, IIS information, PVA, etc.), submit and approve Study setup template, ensuring timely study implementation and negating any impact to case processing delay.

Your Skills and Abilities: BS/BA, RN, Pharmacist, or similar. Minimum of 10 years of Clinical Trial and Post-marketing Pharmacovigilance (PV) experience with 5 years of managerial/leadership experience. Global pharmacovigilance database knowledge is required along with proficient knowledge of global and local regulatory rules and regulations.

About CSL Behring: CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. Our parent company, CSL, headquartered in Melbourne, Australia, employs 32,000 people, and delivers its lifesaving therapies to people in more than 100 countries.